Results 51 to 60 of about 1,180,111 (402)

Parathyroid hormone receptor signalling in osterix-expressing mesenchymal progenitors is essential for tooth root formation

Nature Communications, 2016
Dental root formation is a dynamic process in which mesenchymal cells migrate toward the site of the future root, differentiate and secrete dentin and cementum. However, the identities of dental mesenchymal progenitors are largely unknown.
W. Ono, N. Sakagami, S. Nishimori, N. Ono, H. Kronenberg   +4 more
semanticscholar   +1 more source

Gene Therapy Using Recombinant AAV Type 8 Vector Encoding TNAP‐D10 Improves the Skeletal Phenotypes in Murine Models of Osteomalacia

JBMR Plus, Volume 7, Issue 1, January 2023., 2023
ABSTRACT Hypophosphatasia (HPP), caused by loss‐of‐function mutations in the ALPL gene encoding tissue‐nonspecific alkaline phosphatase (TNAP), is characterized by skeletal and dental hypomineralization that can vary in severity from life‐threatening to milder manifestations only in adulthood.
Flavia Amadeu de Oliveira, Fatma F. Mohamed, Yuka Kinoshita, Sonoko Narisawa, Colin Farquharson, Koichi Miyake, Brian L Foster, Jose Luis Millan   +7 more
wiley   +1 more source

The significance of determining the Intraoperative level of parathormone during surgical treatment of hyperparathyroidism [PDF]

Hospital Pharmacology
Introduction: Surgical treatment is the method of choice for treating primary hyperparathyroidism. Determining parathyroid hormone (PTH) levels intraoperatively allows for real-time monitoring of the functional activity of parathyroid gland tissue and ...
Janičić Stefan D., Stepanović Kristina M., Manojlović Mia S., Bjelajac Dean P., Pejaković Slađana M., Mirković Milan R., Tomić-Naglić Dragana D., Bajkin Ivana A., Ičin Tijana S.   +8 more
doaj   +1 more source

Anabolic Therapies [PDF]

, 2010
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1–34) is the first US Food and Drug Administration–approved anabolic ...
AF Stewart, AP White, AR Poynton, AR Vaccaro, AT Villavicencio, C Lin, CP Coles, EY Chao, F Cosman, G Schmidmaier, JK Burkus, K Singh, LH Hoeppner, M Cormier, M Kneissel, MJ Horwitz, MR John, Nancy E. Lane, R Amerongen van, R Baron, RM Neer, S Govender, SD Glassman, Stuart L. Silverman, T Bellido, V Gopalakrishnan, W Balemans, X Li, X Li   +28 more
core   +2 more sources

Parathyroid Hormone Signaling in Osteocytes

JBMR Plus, 2017
Osteocytes are the most abundant cell type in bone and play a central role in orchestrating skeletal remodeling, in part by producing paracrine‐acting factors that in turn influence osteoblast and osteoclast activity.
Marc N. Wein
semanticscholar   +1 more source

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial

Journal of Bone and Mineral Research, Volume 38, Issue 1, Page 14-25, January 2023., 2023
TransCon PTH is an investigational once‐daily prodrug providing sustained release of active PTH designed to maintain stable PTH levels in the physiological range for 24 hours/day. The PaTHway trial met all primary and key secondary endpoints with statistically significant differences from placebo. Most adverse events (AEs) were mild/moderate. Injection‐
Aliya A Khan, Mishaela R Rubin, Peter Schwarz, Tamara Vokes, Dolores M Shoback, Claudia Gagnon, Andrea Palermo, Claudio Marcocci, Bart L Clarke, Lisa G Abbott, Lorenz C Hofbauer, Lynn Kohlmeier, Susanne Pihl, Xuebei An, Walter Frank Eng, Alden R Smith, Jenny Ukena, Christopher T Sibley, Aimee D Shu, Lars Rejnmark   +19 more
wiley   +1 more source

A Case of Mediastinal Parathyroid Adenoma

Haseki Tıp Bülteni, 2015
Parathyroid adenomas are the most important cause of primary hyperparathyroidism. The diagnosis of primary hyperparathyroidism is established based on the combination of elevated serum calcium and parathyroid hormone levels.
Erkan Akar
doaj   +1 more source

Ixazomib enhances parathyroid hormone-induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor. [PDF]

, 2017
The anabolic action of PTH in bone is mostly mediated by cAMP/PKA and Wnt-independent activation of β-catenin/T-cell factor (TCF) signaling. β-Catenin switches the PTH receptor (PTHR) signaling from cAMP/PKA to PLC/PKC activation by binding to the PTHR ...
Lei, Hong, Qiang, Ya-Wei, Wang, Bin, Yang, Yanmei   +3 more
core   +2 more sources

Parathyroid hormone 1-34 and skeletal anabolic action

Bone & Joint Research, 2017
Intermittently administered parathyroid hormone (PTH 1-34) has been shown to promote bone formation in both human and animal studies. The hormone and its analogues stimulate both bone formation and resorption, and as such at low doses are now in clinical
Liza Osagie-Clouard, A. Sanghani, M. Coathup, T. Briggs, M. Bostrom, G. Blunn   +5 more
semanticscholar   +1 more source

Longitudinal Change in Bone Density, Geometry, and Estimated Bone Strength in Older Men and Women From The Gambia: Findings From the Gambian Bone and Muscle Aging Study (GamBAS)

Journal of Bone and Mineral Research, Volume 38, Issue 1, Page 48-58, January 2023., 2023
ABSTRACT Musculoskeletal aging in the most resource‐limited countries has not been quantified, and longitudinal data are urgently needed to inform policy. The aim of this prospective study was to describe musculoskeletal aging in Gambian adults. A total of 488 participants were recruited stratified by sex and 5‐year age band (aged 40 years and older ...
Mícheál Ó Breasail, Camille Pearse, Ayse Zengin, Landing Jarjou, Cyrus Cooper, Peter R Ebeling, Ann Prentice, Kate A Ward   +7 more
wiley   +1 more source